These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29867132)

  • 21. Synthesis and in vitro activity of new biguanide-containing dendrimers on pathogenic isolates of Acanthamoeba polyphaga and Acanthamoeba griffini.
    Martín-Pérez T; Lozano-Cruz T; Criado-Fornelio A; Ortega P; Gómez R; de la Mata FJ; Pérez-Serrano J
    Parasitol Res; 2019 Jun; 118(6):1953-1961. PubMed ID: 31069536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined drug therapy in the management of granulomatous amoebic encephalitis due to Acanthamoeba spp., and Balamuthia mandrillaris.
    Kulsoom H; Baig AM; Siddiqui R; Khan NA
    Exp Parasitol; 2014 Nov; 145 Suppl():S115-20. PubMed ID: 24726699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pitavastatin loaded nanoparticles: A suitable ophthalmic treatment for Acanthamoeba Keratitis inducing cell death and autophagy in Acanthamoeba polyphaga.
    Sifaoui I; Díaz-Rodríguez P; Rodríguez-Expósito RL; Reyes-Batlle M; López-Arencibia A; Salazar Villatoro L; Castelan-Ramírez I; Omaña-Molina M; Oliva A; Piñero JE; Lorenzo-Morales J
    Eur J Pharm Biopharm; 2022 Nov; 180():11-22. PubMed ID: 36162636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A concise overview of advances in therapeutic efficacy of serum eye drops and their alternatives to treat dry eye syndrome: Verifying the narratives of clinical consistency beyond the periphery of international inconsistency on the methods of collection and application.
    Seghatchian J; van der Meer PF
    Transfus Apher Sci; 2015 Aug; 53(1):85-7. PubMed ID: 26143344
    [No Abstract]   [Full Text] [Related]  

  • 25. Screening of the pathogen box for the identification of anti-Acanthamoeba agents.
    Sifaoui I; Reyes-Batlle M; López-Arencibia A; Chiboub O; Bethencourt-Estrella CJ; San Nicolás-Hernández D; Rodríguez Expósito RL; Rizo-Liendo A; Piñero JE; Lorenzo-Morales J
    Exp Parasitol; 2019 Jun; 201():90-92. PubMed ID: 31059693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of voriconazole anti-Acanthamoeba polyphaga in vitro activity, rat cornea penetration and efficacy against experimental rat Acanthamoeba keratitis.
    Gueudry J; Le Goff L; Compagnon P; Lefevre S; Colasse E; Aknine C; Duval F; François A; Razakandrainibe R; Ballet JJ; Muraine M; Favennec L
    J Antimicrob Chemother; 2018 Jul; 73(7):1895-1898. PubMed ID: 29596605
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chorioretinitis in the contralateral eye of a patient with Acanthamoeba keratitis.
    Johns KJ; O'Day DM; Feman SS
    Ophthalmology; 1988 May; 95(5):635-9. PubMed ID: 3050700
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Amoebicidal activity of α-bisabolol, the main sesquiterpene in chamomile (Matricaria recutita L.) essential oil against the trophozoite stage of Acanthamoeba castellani Neff.
    Hajaji S; Sifaoui I; López-Arencibia A; Reyes-Batlle M; Valladares B; Pinero JE; Lorenzo-Morales J; Akkari H
    Acta Parasitol; 2017 Jun; 62(2):290-295. PubMed ID: 28426414
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corneal staining reductions observed after treatment with Systane Lubricant Eye Drops.
    Christensen MT
    Adv Ther; 2008 Nov; 25(11):1191-9. PubMed ID: 18972076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Therapeutic potential of a combination of two gene-specific small interfering RNAs against clinical strains of Acanthamoeba.
    Lorenzo-Morales J; Martín-Navarro CM; López-Arencibia A; Santana-Morales MA; Afonso-Lehmann RN; Maciver SK; Valladares B; Martínez-Carretero E
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5151-5. PubMed ID: 20855732
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel formulation of glycerin 1% artificial tears extends tear film break-up time compared with Systane lubricant eye drops.
    Gensheimer WG; Kleinman DM; Gonzalez MO; Sobti D; Cooper ER; Smits G; Loxley A; Mitchnick M; Aquavella JV
    J Ocul Pharmacol Ther; 2012 Oct; 28(5):473-8. PubMed ID: 22554205
    [TBL] [Abstract][Full Text] [Related]  

  • 32. G418 induces programmed cell death in Acanthamoeba through the elevation of intracellular calcium and cytochrome c translocation.
    Koutsogiannis Z; MacLeod ET; Maciver SK
    Parasitol Res; 2019 Feb; 118(2):641-651. PubMed ID: 30617503
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cutaneous Acanthamoeba infection in the acquired immunodeficiency syndrome: response to multidrug therapy.
    Hunt SJ; Reed SL; Mathews WC; Torian B
    Cutis; 1995 Nov; 56(5):285-7. PubMed ID: 8565615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cellulose degradation: a therapeutic strategy in the improved treatment of Acanthamoeba infections.
    Lakhundi S; Siddiqui R; Khan NA
    Parasit Vectors; 2015 Jan; 8():23. PubMed ID: 25586209
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic agents and biocides for ocular infections by free-living amoebae of Acanthamoeba genus.
    Carrijo-Carvalho LC; Sant'ana VP; Foronda AS; de Freitas D; de Souza Carvalho FR
    Surv Ophthalmol; 2017; 62(2):203-218. PubMed ID: 27836717
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug Target Discovery Methods In Targeting Neurotropic Parasitic Amoebae.
    Baig AM; Waliani N; Karim S
    ACS Chem Neurosci; 2018 Feb; 9(2):162-164. PubMed ID: 29286622
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro activity of 1H-phenalen-1-one derivatives against Acanthamoeba castellanii Neff and their mechanisms of cell death.
    López-Arencibia A; Reyes-Batlle M; Freijo MB; McNaughton-Smith G; Martín-Rodríguez P; Fernández-Pérez L; Sifaoui I; Wagner C; García-Méndez AB; Liendo AR; Bethencourt-Estrella CJ; Abad-Grillo T; Piñero JE; Lorenzo-Morales J
    Exp Parasitol; 2017 Dec; 183():218-223. PubMed ID: 28916457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Abietane diterpenoids from Salvia sclarea transformed roots as growth inhibitors of pathogenic Acanthamoeba spp.
    Kuźma Ł; Derda M; Hadaś E; Wysokińska H
    Parasitol Res; 2015 Jan; 114(1):323-7. PubMed ID: 25382125
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of In Vitro Antiamoebic Activity of Antimicrobial Agents Against Clinical Acanthamoeba Isolates.
    Nakaminami H; Tanuma K; Enomoto K; Yoshimura Y; Onuki T; Nihonyanagi S; Hamada Y; Noguchi N
    J Ocul Pharmacol Ther; 2017 Oct; 33(8):629-634. PubMed ID: 28704121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cellulose biosynthesis pathway is a potential target in the improved treatment of Acanthamoeba keratitis.
    Dudley R; Alsam S; Khan NA
    Appl Microbiol Biotechnol; 2007 May; 75(1):133-40. PubMed ID: 17225099
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.